| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| CA-170 | CA-170; AUPM-170 | Phase 3 Clinical | Aurigene | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | 詳細 |
| Solnerstotug | SNS-101; SNS-VISTA | Phase 2 Clinical | Sensei Biotherapeutics Inc | Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 詳細 |
| Trovostobart | KVA-12123; KVA-12.1 | Phase 2 Clinical | GigaGen Inc | Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Uterine Neoplasms | 詳細 |
| Onvatilimab | CI-8993; JNJ-61610588 | Phase 1 Clinical | Immunext Inc, Johnson & Johnson Innovative Medicine | Neoplasms; Solid tumours | 詳細 |
| HMBD-002 | HMBD-002 | Phase 1 Clinical | Hummingbird Bioscience | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 詳細 |
| PMC-309 | PMC-309 | Phase 1 Clinical | Pharmabcine | Neoplasms; Solid tumours | 詳細 |
| TBS-2025 | TBS-2025 | Phase 1 Clinical | Kintara Therapeutics Inc | Leukemia, Myeloid, Acute | 詳細 |
| LFD-200 | LFD-200 | Phase 1 Clinical | Lifordi Immunotherapeutics Inc | Arthritis, Rheumatoid | 詳細 |